COVID-19 As Another Trigger for HBV Reactivation: Clinical Case and Review of Literature

Overview

Journal Pathogens

Date 2022 Jul 27

PMID 35890060

Authors

Caterina Sagnelli

Laura Montella

Pierantonio Grimaldi

Mariantonietta Pisaturo

Loredana Alessio

Stefania De Pascalis

Evangelista Sagnelli

Nicola Coppola

Affiliations

Soon will be listed here.

Abstract

Universal hepatitis B virus (HBV) vaccination has been applied for years in most countries, but HBV infection remains an unresolved public health problem worldwide, with over one-third of the world's population infected during their lifetime and approximately 248 million hepatitis B surface antigen (HBsAg) chronic carriers. HBV infection may reactivate with symptomatic and sometimes life-threatening clinical manifestations due to a reduction in the immune response of various origins, due to chemotherapy or immunosuppressive therapy, treatments increasingly practiced worldwide. SARS-CoV-2 and its COVID-19 associated disease have introduced new chances for HBV reactivation due to the use of dexamethasone and tocilizumab to counteract the cytokine storm. This could and should be prevented by accurate screening of HBV serologic markers and adequate pharmacologic prophylaxis. This article describes the case of a patient with COVID-19 who developed HBV reactivation and died of liver failure and analyzes published data on this setting to provide useful information to physicians who manage these patients during the SARS-CoV-2 pandemic.

Citing Articles

Chronic Hepatitis B and COVID-19 Clinical Outcomes in the United States: A Multisite Retrospective Cohort Study.

Yendewa G, Olasehinde T, Mulindwa F, Salata R, Mohareb A, Jacobson J Open Forum Infect Dis. 2025; 12(2):ofaf013.

PMID: 39896985 PMC: 11786054. DOI: 10.1093/ofid/ofaf013.

Effect of SARS-CoV-2 infection on liver function in patients with hepatitis B.

Sun T, Chi H, Wang J, Zheng Y, Zhu H, Zhao J BMC Infect Dis. 2024; 24(1):1428.

PMID: 39695950 PMC: 11654415. DOI: 10.1186/s12879-024-10324-0.

Risk of Hepatitis B Virus Reactivation in COVID-19 Patients Receiving Immunosuppressive Treatment: A Prospective Study.

Mihai N, Olariu M, Ganea O, Adamescu A, Molagic V, Arama S J Clin Med. 2024; 13(20).

PMID: 39457983 PMC: 11508539. DOI: 10.3390/jcm13206032.

Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications.

Nasir N, Khanum I, Habib K, Wagley A, Arshad A, Majeed A Hepatol Forum. 2024; 5(3):139-149.

PMID: 39006140 PMC: 11237249. DOI: 10.14744/hf.2023.2023.0025.

Hepatitis B Reactivation and Liver Failure Because of COVID-19 Infection.

Mushtaq M, Colletier K, Moghe A ACG Case Rep J. 2024; 11(7):e01397.

PMID: 38939351 PMC: 11210963. DOI: 10.14309/crj.0000000000001397.

References

Tonziello G, Pisaturo M, Sica A, Ferrara M, Sagnelli C, Pasquale G . Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection. 2012; 41(1):225-9. DOI: 10.1007/s15010-012-0305-y. View

Monari C, Sagnelli C, Maggi P, Sangiovanni V, Numis F, Gentile I . More Severe COVID-19 in Patients With Active Cancer: Results of a Multicenter Cohort Study. Front Oncol. 2021; 11:662746. PMC: 8139554. DOI: 10.3389/fonc.2021.662746. View

Lau G, Sharma M . Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020; 14(4):415-428. PMC: 7245190. DOI: 10.1007/s12072-020-10054-w. View

Mussini C, Falcone M, Nozza S, Sagnelli C, Parrella R, Meschiari M . Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). Clin Microbiol Infect. 2020; 27(3):389-395. PMC: 7833273. DOI: 10.1016/j.cmi.2020.12.011. View

Shih C, Chou S, Yang C, Huang J, Choijilsuren G, Jhou R . Control and Eradication Strategies of Hepatitis B Virus. Trends Microbiol. 2016; 24(9):739-749. DOI: 10.1016/j.tim.2016.05.006. View

Kuo M, Tseng C, Lu M, Tung C, Tseng K, Huang K . Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021; 66(11):4026-4034. PMC: 7775841. DOI: 10.1007/s10620-020-06725-1. View

Ogawa E, Furusyo N, Murata M, Toyoda K, Hayashi T, Ura K . Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV. Liver Int. 2017; 38(1):76-83. DOI: 10.1111/liv.13496. View

Fidan S, Capkin E, Arica D, Durak S, Okatan I . Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy. Int J Rheum Dis. 2020; 24(2):254-259. DOI: 10.1111/1756-185X.14034. View

Chen Y, Yang S, Chen D . Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. J Microbiol Immunol Infect. 2017; 52(1):1-8. DOI: 10.1016/j.jmii.2017.10.002. View

10.

Chen L, Huang S, Yang J, Cheng X, Shang Z, Lu H . Clinical characteristics in patients with SARS-CoV-2/HBV co-infection. J Viral Hepat. 2020; 27(12):1504-1507. PMC: 7404861. DOI: 10.1111/jvh.13362. View

11.

Zhang C, Shi L, Wang F . Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. PMC: 7129165. DOI: 10.1016/S2468-1253(20)30057-1. View

12.

Lok A, Ward J, Perrillo R, McMahon B, Liang T . Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med. 2012; 156(10):743-5. PMC: 3469313. DOI: 10.7326/0003-4819-156-10-201205150-00013. View

13.

Moghoofei M, Mostafaei S, Ashraf-Ganjouei A, Kavosi H, Mahmoudi M . HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis. Microb Pathog. 2017; 114:436-443. DOI: 10.1016/j.micpath.2017.12.014. View

14.

Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis I . Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2020; 21(2):167-179. PMC: 7598940. DOI: 10.1007/s10238-020-00671-y. View

15.

Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L . SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020; 73(4):807-816. PMC: 7211738. DOI: 10.1016/j.jhep.2020.05.002. View

16.

Zou X, Fang M, Li S, Wu L, Gao B, Gao H . Characteristics of Liver Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection. Clin Gastroenterol Hepatol. 2020; 19(3):597-603. PMC: 7294291. DOI: 10.1016/j.cgh.2020.06.017. View

17.

Ito S . Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center. Mod Rheumatol. 2020; 31(4):775-782. DOI: 10.1080/14397595.2020.1832731. View

18.

Liu R, Zhao L, Cheng X, Han H, Li C, Li D . Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study. Liver Int. 2020; 41(4):720-730. DOI: 10.1111/liv.14774. View

19.

Zhang X, Zhou Y, Chen C, Fang W, Cai X, Zhang X . Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer. 2019; 7(1):322. PMC: 6873745. DOI: 10.1186/s40425-019-0808-5. View

20.

Agarwal A, Hunt B, Stegemann M, Rochwerg B, Lamontagne F, Ac Siemieniuk R . A living WHO guideline on drugs for covid-19. BMJ. 2020; 370:m3379. DOI: 10.1136/bmj.m3379. View